|
- Sarepta Therapeutics | Biopharmaceutical Company for Rare Diseases
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases Learn more about Sarepta
- Sarepta Therapeutics Provides Statement on ELEVIDYS
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases
- Investor Relations | Sarepta Therapeutics, Inc.
The Investor Relations website contains information about Sarepta Therapeutics, Inc 's business for stockholders, potential investors, and financial analysts
- About Our Company - Sarepta Therapeutics
Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short
- Sarepta Therapeutics Announces Strategic Restructuring and Pipeline . . .
Sarepta will report its final and complete second quarter 2025 financial results in early August 2025 Refocused Pipeline on siRNA platform Sarepta’s dedication to advancing genetic medicine remains steadfast
- Our Pipeline | Sarepta Therapeutics
Sarepta’s industry leading pipeline is comprised of over 40 programs in various stages of development across 3 technologies, RNA, gene therapy and gene editing, and multiple therapeutic areas including neuromuscular, CNS and cardiology
- Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in . . .
Today, Sarepta Therapeutics notified the U S Food and Drug Administration (FDA) of its decision to voluntarily and temporarily pause all shipments of ELEVIDYS (delandistrogene moxeparvovec) for Duchenne muscular dystrophy in the United States, effective close of business Tuesday, July 22, 2025
- News Press Releases - Sarepta Therapeutics
Read news and articles from Sarepta, a global biotechnology company developing potentially life-changing precision genetic medicine
|
|
|